Navigation Links
UCI researchers create new strategy for highly selective chemotherapy delivery
Date:9/25/2009

Irvine, Calif. UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs.

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

Using this technology, the research team demonstrated that the doxorubicin was directed almost entirely to the targeted site with virtually no uptake by other organs, including lung, kidney and heart.

Their study appears online in the International Journal of Pharmaceutics.

Their approach is based on the fact that all tissues and organs, including all tumors, are surrounded by a dense region of sugar-containing molecules called polysaccharides. Most importantly, the particular chemical composition of the polysaccharides is different in each tissue and organ of the body. The chemical compositions of the polysaccharides of tumor regions are also different from normal tissue.

The research team developed a nanocarrier system that can recognize specific types of polysaccharide, and has demonstrated effective, organ-specific delivery of nanocarriers, and their therapeutic contents, based upon this polysaccharide-targeting approach.

In their study, the researchers used a peptide derived from a protein found in the microorganism Plasmodium, which is an organism well-known for its exceptional ability to exclusively target the polysaccharides of liver following entry into the bloodstream.

The drug doxorubicin is a chemotherapeutic agent commonly used as treatment for a variety of cancers. Although it is an effective anti-cancer agent, the usefulness of doxorubicin is compromised by its serious side effects on normal tissue. When administered in a chemotherapeutic regimen, doxorubicin distributes widely in the body, including the heart, rather than specifically in tumor regions.

The serious heart damage that results from systemic administration places limits on the dosage that a patient can receive. By encapsulating doxorubicin into a liposome package and including a peptide targeting message on the carrier, Longmuir, Robertson and co-workers demonstrated that doxorubicin can be effectively delivered to the liver, and away from the heart, with a specificity of greater than 100:1.

The next step in this investigation is to test the properties of the delivery system in several experimental cancer models. Liposomes with peptides are being developed that specifically address the unique features of tumors, in order to rapidly and effectively deliver chemotherapeutic agents to tumor regions.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. UCI researchers create new strategy for highly-selective chemotherapy delivery
2. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
3. VA Honors Eye Researchers With Olin Teague Award
4. Researchers find drug-eluting stents safe, effective for PCI in diabetics
5. Researchers Propose Improved Cervical Cancer Screening
6. Researchers Perfect the View of Heart Disease
7. Mayo Clinic researchers lead national trial testing new treatment for chronic, severe indigestion
8. Indiana U medical researchers boost research and jobs with stimulus legislation grants
9. Canadian researchers discover the first-ever link between intelligence and curiosity
10. MUSC Researchers Concerned About Online Drug Availability
11. UCLA researchers develop biomarker for rapid relief of major depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance ... insurance and financial preparation services, is providing an update on a charitable event ... Rock City Rescue is a locally recognized nonprofit that provides shelter and care ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: